title: [S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties.
abstract: A rational, chemical, synthetic effort to identify promising low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists for use as antiepileptic drugs led to the discovery of AR-R 15035AR, or [RS]-alpha-phenyl-2-pyridine-ethanamine.2HCl. Chiral separation followed by intensive in vivo screening resulted in the selection of the [S] enantiomer, AR-R 15896AR, as the best compound for further preclinical development. AR-R 15896AR prevented tonic seizures in rodents for up to 6 to 8 h in response to maximal electroshock (MES), 4-aminopyridine, bicuculline, or strychnine, as well as characteristic seizures following injections of N-methyl-DL-aspartic or kainic acids. AR-R 15896AR was ineffective in two kindling models of epilepsy, did not produce tolerance to MES, and was devoid of proconvulsant and phencyclidine-like properties in mice and rats, respectively. Therapeutic indices for AR-R 15896AR were comparable to or exceeded those for standard anticonvulsants. Orally administered AR-R 15896AR rapidly entered the rat brain and was eliminated in parallel from the plasma and plasma-free compartment. A dose-response relationship between plasma and brain levels after p.o. or i.v. administration of AR-R 15896AR and protection against MES was highly correlative. The time course for loss of protection against MES mirrored the elimination of the compound from brain and plasma. The total brain concentration (25 microM) of drug at the ED50 value (approximately 3 mg/kg) for protection against MES seizures was consistent with the reported affinity of AR-R 15896AR at the N-methyl-D- aspartic acid binding site (IC50 value = 1.3 microM). The present findings demonstrated the attractiveness of AR-R 15896AR as a candidate for further development to treat epilepsy.
authors.affiliation: Astra Arcus, Rochester, New York, USA.
authors.forename: G C
authors.initials: GC
authors.lastname: Palmer
authors.forename: R J
authors.initials: RJ
authors.lastname: Murray
authors.forename: C L
authors.initials: CL
authors.lastname: Cramer
authors.forename: M L
authors.initials: ML
authors.lastname: Stagnitto
authors.forename: M K
authors.initials: MK
authors.lastname: Knowles
authors.forename: L R
authors.initials: LR
authors.lastname: Freedman
authors.forename: M S
authors.initials: MS
authors.lastname: Eismann
authors.forename: N
authors.initials: N
authors.lastname: Mahmood
authors.forename: M
authors.initials: M
authors.lastname: Balestra
authors.forename: A R
authors.initials: AR
authors.lastname: Borrelli
authors.forename: T J
authors.initials: TJ
authors.lastname: Hudzik
authors.forename: D J
authors.initials: DJ
authors.lastname: McCarthy
mesh_terms: D015761:4-Aminopyridine; D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001640:Bicuculline; D004558:Electric Stimulation; D007608:Kainic Acid; D008297:Male; D051379:Mice; D016202:N-Methylaspartate / Q000031:analogs & derivatives; D010433:Pentylenetetrazole; D010852:Picrotoxin; D011725:Pyridines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D003294:Seizures, Febrile / Q000188:drug therapy; D013331:Strychnine; D013997:Time Factors; D014886:Weaning
chemical_list: D015761:4-Aminopyridine; D000927:Anticonvulsants; D001640:Bicuculline; D007608:Kainic Acid; D016202:N-Methylaspartate; D010433:Pentylenetetrazole; D010852:Picrotoxin; D011725:Pyridines; D013331:Strychnine; C096406:alpha-phenyl-2-pyridineethanamine dihydrochloride; C083705:N-methyl-DL-aspartic acid